malaysiangKUALA LUMPUR, Dec 14 — Tessa Therapeutics Ltd (Tessa), a clinical-stage cell therapy company, has announced clinical data from the pilot stage of the ongoing Phase 2 CHARIOT trial (NCT04268706) of TT11, the Company’s autologous CD30 chimeric antigen receptor T-cell (CAR-T) therapy.
“We believe that Tessa’s CD30-CAR-T cell therapy, with its promising efficacy and excellent safety profile, has the potential to address clear unmet need in the treatment of cHL,” said Chief Medical Officer and Chief Scientific Officer of Tessa Therapeutics, Ivan Horak, M.D.
Based on a statement, the results demonstrated a favourable safety profile and promising efficacy in relapsed or refractory CD30-positive classical Hodgkin lymphoma (cHL) patients, with a complete response (CR) rate of 57.1 per cent and an overall response rate (ORR) of 71.4 per cent.
The data was presented in an oral poster presentation at the 63rd Annual Meeting of the American Society of Hematology (ASH) and follows a poster presented on Dec 11 reporting favourable safety and efficacy data in a Phase 1 trial of Tessa’s “off-the-shelf” CD30-CAR EBVST cell therapy in relapsed or refractory CD30-positive lymphomas.
The ASH poster is entitled ‘Safety and Efficacy Profile of Autologous CD30.CAR-T-Cell Therapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (CHARIOT Trial)’.
As of the data cutoff, TT11’s CD30-CAR-T cells, initially detected three hours post infusion, had persisted for more than 42 days post-infusion. The cells showed strong expansion that peaked seven to 14 days after treatment.
TT11 remained well tolerated with no reports of neurotoxicity or grade 3 or higher CRS (cytokine release syndrome). One patient experienced a Grade 1 CRS which resolved within five days.
Source: BERNAMA News Agency
